Aktis Oncology, Inc. (AKTS) News
Follow Aktis Oncology, Inc. (AKTS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
AKTIS Oncology initiated as Outperform by Oppenheimer
AKTIS Oncology was initiated with an Outperform rating by Oppenheimer.
EQUITY | Sep 09, 2026, 02:46 PM UTC
L
Aktis Oncology to present at September investor conferences
Aktis Oncology said it will present at upcoming September investor conferences, according to a company announcement.
EQUITY | Sep 09, 2026, 12:03 PM UTC
L
AKTS - Aktis Oncology to Present at Upcoming September Investor Conferences
AKTS - Aktis Oncology to Present at Upcoming September Investor Conferences
EQUITY | Sep 09, 2026, 12:01 PM UTC
L
Wedbush initiates AKTS at Outperform, $35 price target
Wedbush initiates AKTS at Outperform with a $35.00 price target; the alert supplies no additional catalyst or rationale.
EQUITY | Aug 19, 2026, 11:55 AM UTC
L
BMO, Wedbush, Wolfe and RBC issue stock initiations
BMO, Wedbush, Wolfe, RBC and Cantor initiate coverage with ratings changes on AKTS, ALNY, ASND, BCAX, BMRN, CATX, PRME, AFL, AGMB, COR and MCK.
EQUITY | Aug 19, 2026, 11:09 AM UTC
L
Wedbush starts AKTS at Outperform with $35 target
Wedbush initiates AKTS with an Outperform rating and a $35 price target.
EQUITY | Aug 19, 2026, 11:01 AM UTC
L
Aktis Oncology reports Q2 2026 financial results and business highlights
Aktis Oncology (AKTS) reports financial results and business highlights for the second quarter of 2026.
EARNINGS | Aug 13, 2026, 08:01 PM UTC
L
AKTS PBLS HIMS Today and tomorrow, an FDA advisory committee will mull whether compounding pharmacies should be allowed to manufacture seven
AKTS PBLS HIMS Today and tomorrow, an FDA advisory committee will mull whether compounding pharmacies should be allowed to manufacture seven peptides, in particular. This could mean a clash between career FDA scientists,
REGULATION | Jul 23, 2026, 12:13 PM UTC
L
AKTS PBLS HIMS U.S. FDA advisers this week will weigh whether seven Popular peptides can be compounded by licensed pharmacies, but even if r
AKTS PBLS HIMS U.S. FDA advisers this week will weigh whether seven Popular peptides can be compounded by licensed pharmacies, but even if regulators decline to expand access, industry participants say consumer demand is
REGULATION | Jul 22, 2026, 11:08 AM UTC
L
Aktis Oncology Insider Sold Shares Worth $1,388,701, According to a Recent SEC Filing
() -- Akos Czibere, Chief Medical Officer, on July 08, 2026, sold 50,000 common shares in Aktis Oncology (AKTS) for $1,388,701. SEC Filing: Copyright © 2026. All rights reserved. does not provide investment advice. Unaut
REGULATION | Jul 10, 2026, 10:26 AM UTC
H
DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Nasdaq Composite falling around 1% on Tuesday. Shares of DigitalOcean Holdings Inc (NYSE: DOCN ) rose sharply after the company announced it expects a year-over-year increase in second-qu
EARNINGS | Jul 07, 2026, 02:00 PM UTC